Novo Nordisk and Amazon Web Services (AWS) announced a strategic partnership to accelerate drug discovery and modernize Novo Nordisk’s operations using artificial intelligence and cloud technologies. The companies established a new AI co-innovation hub in London, bringing together AWS engineers and AI specialists with Novo Nordisk scientists and research and development teams. The collaboration will use AI technologies alongside Novo Nordisk’s data and scientific expertise to help shorten the path from identifying a drug target to administering a potential medicine in first-in-human studies. Novo Nordisk has selected AWS as its preferred cloud provider and strategic AI partner. The companies have already achieved measurable results, including reducing the time required for clinical documentation and providing AI-enabled productivity tools to more than 25,000 employees. The partnership will use AWS technologies including Amazon Bio Discovery and Amazon Bedrock to support drug-target identification, therapy design, and the integration of genomic, imaging, and clinical data. Novo Nordisk also plans to use Amazon Bedrock AgentCore to deploy AI agents aimed at improving operational efficiency. Mike Doustdar, President and CEO of Novo Nordisk, said: “Partnering with AWS is about making AI a driver of innovation across Novo Nordisk.” AWS CEO Matt Garman said the collaboration is focused on using AI and cloud technologies to help Novo Nordisk shorten drug discovery timelines, securely process complex datasets, and scale research findings across therapeutic areas. The agreement builds on an existing relationship between Novo Nordisk and Amazon, including Amazon Pharmacy, Amazon Ads,